Psychedelic-assisted therapy, known as PAT, is an emerging therapeutic approach that combines the controlled use of certain psychedelic substances with a structured, supervised psychotherapeutic process. Unlike recreational use, PAT takes place in a safe therapeutic setting, with specifically trained professionals and defined clinical goals.
In broad terms, PAT rests on several key elements. First, a psychedelic substance such as psilocybin, MDMA or ketamine is used, always at carefully controlled doses. Second, the setting is crucial: the experience takes place in a structured, safe environment designed to minimise risk. The intervention also includes continuous support from trained therapists. Finally, the main aim is to facilitate deep psychological processes, catalyse therapeutic progress and encourage lasting change.
A central point about psychedelic-assisted therapy is that it is not limited to the session with the substance. The process includes preparation sessions beforehand and integration sessions afterwards, which help make sense of the experience and turn it into concrete changes in everyday life.
Main areas of application and research
PAT is currently at different stages of clinical research. So although preliminary results are promising, many of its applications are not yet part of standard treatment.
Mood disorders
One of the most studied areas is mood disorders, especially depression. For treatment-resistant major depression, the most researched substance is psilocybin. Ketamine, for its part, has already been approved in certain formulations and clinical contexts. In these cases the potential mechanism includes increased neuroplasticity, breaking up ruminative thought patterns and enabling a more flexible emotional reconnection.
PAT has also shown clinical interest in depression and anxiety linked to serious or terminal illness. Here psilocybin has been studied for its ability to reduce fear of death, improve spiritual wellbeing, increase acceptance of one’s situation and, as a result, improve quality of life.
Post-traumatic stress disorder
Another relevant field of research is post-traumatic stress disorder. Here the most studied substance is MDMA. From a neuropsychological point of view, MDMA is thought to reduce amygdala hyperactivity, increase feelings of trust and empathy, and make it possible to access traumatic memories without being overwhelmed. As a result, the therapeutic alliance is strengthened and trauma processing is supported.
Substance use disorders
PAT is also being investigated as a possible tool in treating addictions, such as alcohol dependence or smoking. Psilocybin has mainly been the most studied substance in this area, although ibogaine has also drawn interest, albeit with greater risks and more complex research. In these cases the potential mechanism is to interrupt addictive patterns of thought and behaviour, increase motivation to change and enable deep insight into the underlying causes of the addiction.
Anxiety disorders
For anxiety disorders, research is more preliminary but growing. Applications have been explored in generalised anxiety disorder, social anxiety and obsessive-compulsive disorder. Psilocybin in particular has been studied for its ability to help re-evaluate anxious or obsessive thought patterns and reduce experiential avoidance, much as has been observed in depression.
Other emerging areas
Beyond the applications above, there are emerging areas of research. These include eating disorders such as anorexia, palliative care and existential distress, as well as personal growth and wellbeing in healthy people. However, these last applications have a more limited scientific base in formal clinical settings.
Key considerations on psychedelic-assisted therapy
It is important to stress that PAT is, to a large extent, still at the research stage. It should therefore not be understood as a widely available treatment or as a form of self-medication. Professional supervision is essential and requires specifically trained therapists and a controlled medical or clinical setting.
There are also clear risks and contraindications. PAT is not suitable for everyone, especially people with a history of psychosis or certain medical conditions, such as some cardiovascular problems. Adverse psychological effects can also occur, such as intense anxiety or episodes of paranoia.
Finally, the legal framework is a decisive factor. In most countries, including Spain, access to PAT is highly restricted and usually limited to authorised clinical trials. In this context, integration afterwards becomes crucially important, since it allows the experience to be turned into real and lasting therapeutic change.
In short, psychedelic-assisted therapy is emerging as a potentially powerful tool for tackling complex, treatment-resistant mental health problems. Its safe and effective use, however, depends decisively on the therapeutic context, professional supervision and an adequate legal framework.

